Activated microglia and alpha 7 nicotinic acetylchorine receptors in schizophrenia: A PET study (for smoker)
Not Applicable
Recruiting
- Conditions
- schizophrenia
- Registration Number
- JPRN-UMIN000038171
- Lead Sponsor
- Hamamatsu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
- With past or current history of serious medical illness and/or brain organic diseases - History of alcoholics or substance abuse or addiction - In pregnancy - No family support - Taking antiallergic or anticholinergic drugs - Difficult for taking MRI imaging
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The binding potential of both 11C-DPA713 and 11C-MeQAA in hippocampus and prefrontal cortex
- Secondary Outcome Measures
Name Time Method cognitive function test (Cog state, TMT, stroop, VFT) Positive and Negative Symptom Scale (PANSS)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What role do alpha-7 nicotinic acetylcholine receptors play in microglial activation in schizophrenia patients who smoke?
How does PET imaging of activated microglia correlate with cognitive deficits in nicotine-dependent schizophrenia subtypes?
Are alpha-7 nicotinic receptor agonists effective in reducing neuroinflammation compared to standard antipsychotics in schizophrenia?
Which biomarkers measured via PET predict treatment response to alpha-7 nicotinic receptor modulation in schizophrenia smokers?
What adverse events are associated with alpha-7 nicotinic receptor targeting in schizophrenia patients with nicotine dependence?